VVOSVivos Therapeutics, Inc.

Nasdaq vivos.com


$ 5.17 $ 1.90 (58.1 %)    

Wednesday, 18-Sep-2024 13:29:18 EDT
QQQ $ 474.07 $ -0.49 (-0.1 %)
DIA $ 417.51 $ 0.61 (0.15 %)
SPY $ 563.70 $ -0.16 (-0.03 %)
TLT $ 100.35 $ 0.03 (0.03 %)
GLD $ 237.76 $ -0.43 (-0.18 %)
$ 2.8
$ 3.27
$ 5.19 x 100
-- x --
$ 3.04 - $ 5.92
$ 1.91 - $ 48.79
168,207
na
9.52M
$ 4.11
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 03-28-2024 12-31-2023 10-K
4 08-16-2023 06-30-2023 10-Q
5 06-08-2023 03-31-2023 10-Q
6 03-30-2023 12-31-2022 10-K
7 12-20-2022 09-30-2022 10-Q
8 12-20-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-31-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-25-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 vivos-therapeutics-says-it-is-poised-to-disrupt-pediatric-sleep-apnea-market-secures-fda-approval-for-dna-appliance-to-treat-snoring-in-children

The FDA has granted 510(k) clearance to Vivos Therapeutics' DNA oral appliance for treating moderate to severe obstructive ...

 vivos-therapeutics-secures-fda-510k-clearance-to-treat-moderate-to-severe-pediatric-sleep-apnea-and-snoring

Vivos' DNA appliance now approved to reduce snoring and treat moderate to severe OSA in children aged 6 to 17

 ascendiant-capital-maintains-buy-on-vivos-therapeutics-raises-price-target-to-66

Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and raises the price target from...

 vivos-therapeutics-q2-2024-gaap-eps-060-beats-092-estimate-sales-405m-beat-360m-estimate

Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(...

 vivos-therapeutics-q1-eps-163-up-from-172-yoy-sales-342m-down-from-386m-yoy

Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(1.63) per share. This is a 5.23 percent increase over losses of...

 whats-going-on-with-vivos-therapeutics-stock

Vivos Therapeutics shares are trading lower Tuesday. The company filed a prospectus related to the resale of up to 1.73 million...

Core News & Articles
Market-Moving News for April 9th
04/09/2024 12:56:00

LASE: 167% | Laser Photonics shares are trading higher after the company announced it secured an order for its LaserTower COMPA...

 vivos-therapeutics-flagship-care-oral-medical-devices-receive-full-approval-for-medicare-reimbursement

 Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ:VVOS), a leading medical device and technology company specializin...

 vivos-therapeutics-has-received-a-notice-of-allowance-for-its-us-patent-application-17522740-titled-vibrational-oral-appliance-with-mandibular-advancements-to-provide-relief-from-sleep-disordered-breathing-sleep-apnea-andor-snoring

https://patentcenter.uspto.gov/applications/17522740/ifw/docs 

 why-doma-holdings-shares-are-trading-higher-by-around-34-here-are-20-stocks-moving-premarket

Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transa...

 vivos-therapeutics-q4-2023-gaap-eps-305-misses-191-estimate-sales-3248m-miss-3406m-estimate

Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(3.05) per share which missed the analyst consensus estimate of ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION